cell-free DNA
CareDx Stock Rises Following American Society of Transplant Surgeons' Position Statement on Test Use
ASTS supports the use of dd-cfDNA as a biomarker of kidney transplant rejection, as well as peripheral blood gene expression profiling to help rule out heart transplant rejection.
Lucence Liquid Biopsy Test to Receive Medicare Reimbursement in Lung Cancer
Lucence's amplicon-based LiquidHallmark liquid biopsy assay will now be covered under a finalized local coverage determination from Medicare contractor Palmetto.
Natera Files Second Patent Infringement Suit Against NeoGenomics Subsidiary Inivata
The suit was filed the same day Natera received a new patent covering its patient-specific residual cancer testing and monitoring methods.
Liver Cancer Detection Score Developed With Machine Learning Analysis of Blood Plasma DNA Fragments
Researchers used machine learning to come up with a cell-free DNA 'fragmentome'-based score for finding hepatocellular carcinoma cases from blood plasma samples.
NIH-Developed Blood Test Shows Promise for Predicting Pulmonary Arterial Hypertension Severity
Premium
Research results suggest the cell-free DNA test could improve measures of disease progress and patient survivability, which could help doctors prolong patients' lives.